David Ferry

(Former)

View graph of relations

Recent publications

Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET)
Gary Middleton, David Ferry & 3 others, , 1 Feb 2017, In: Journal of Clinical Oncology . 35, 4, p. 402-411 10 p.

Research output: Contribution to journal › Article › peer-review

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Gary Middleton, David Ferry & 7 others, , Jun 2013, In: European Journal of Cancer. 49, 9, p. 2116-2125 10 p.

Research output: Contribution to journal › Article › peer-review

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Gary Middleton, David Ferry & 2 others, , May 2013, In: The Lancet Oncology. 14, 6, p. 481-9 9 p.

Research output: Contribution to journal › Article › peer-review

View all (14)